StockData

WEED, Inc. (BUDZ) stock

BUDZOTCServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.02−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $2.67MP/E –Yield –

WEED, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $2.67M.

Revenue
$0
TTM Q2 2026
Operating income
-$1.05M
TTM Q2 2026
EPS, diluted
-$0.01
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$2.67M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$1.10M
EPS, diluted
-$0.01
Book value per share
-$0.01
Diluted shares
148M

Trading

Previous close
$0.02
Open
$0.02
Day's range
$0.02 – $0.02
Volume
133,274
Average volume (20 days)
65,597

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodBUDZS&P 500DifferenceBUDZ per yearS&P 500 per year
1 month-34.3%+0.6%−34.9 pts
3 months-30.1%+3.4%−33.5 pts
Year to date-58.4%+13.3%−71.7 pts
1 year-58.1%+16.6%−74.8 pts
3 years-80.0%+86.4%−166.4 pts-41.5%+23.1%
5 years-94.4%+81.9%−176.2 pts-43.8%+12.7%
10 years-97.9%+318.9%−416.7 pts-32.0%+15.4%

Thirteen years at a glance

Fiscal years 2009 to 2025 and trailing twelve months, USD

Revenue

$0

Gross profit

–

Operating income

-$1.05M

Net income

-$1.10M

EPS, diluted

-$0.01

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases WEED filed with the SEC as exhibits to Form 8-K or 6-K

About WEED

Services-Commercial Physical & Biological Research

WEED, Inc. operates as a multi-national bio-pharmaceutical and real estate holding company focused on researching, developing, and applying cannabis-derived compounds for medical and industrial use. Through its operating subsidiaries, the company conducts cannabis genomic studies and breeding programs to classify the cannabis plant genus, preserve genetic cultivars, and develop validated strains aimed at treating human and animal ailments. It also holds a proprietary seedbank of cannabis and hemp genetics, maintains industrial hemp licenses for cultivation, nursery, and processing operations, and explores digital asset and technology integrations. Its primary targets and intended clientele include medical research centers, bio-pharmaceutical companies, healthcare professionals, and commercial medicinal markets.

Company profile, executives and history

WEED stock: common questions

What is WEED's stock price?

BUDZ closed at $0.02 on Oct 19, 2026, down 10.00% on the day.

What is WEED's market cap?

WEED was worth $2.67M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is BUDZ's P/E ratio?

WEED lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.01), so it has no meaningful P/E ratio.

How much revenue does WEED make?

WEED reported revenue of $0 for the twelve months to Jun 30, 2026.

Does WEED pay a dividend?

No. WEED has not paid a cash dividend over the last twelve months.

How has BUDZ stock performed over the past year?

Including dividends, BUDZ returned -58.1% over the past year, against +16.6% for the S&P 500.

Who are WEED's competitors?

Companies most similar to WEED by business, industry and size include CBIH, CRL, INCY, ABSI, MEDP.

See a number that looks wrong?